Bioassay and Reaction Biology Corporation mark first anniversary of merger

news-releasesBioassay GmbH
January 18th 2024

Heidelberg, Germany: – Specialist bioanalytical contract research organization (CRO) Bioassay GmbH and US-based Reaction Biology Corporation (Reaction) celebrated the first anniversary of their merger, which further expanded Reaction’s comprehensive portfolio of drug discovery and development services, and expanded Bioassay’s ability to serve customers globally.

On December 2, 2022, the two companies announced that they reached definitive agreement for Reaction to acquire Bioassay, including its wholly owned subsidiary, Peptide Specialty Laboratories, also based in Heidelberg. This added Bioassay’s capabilities and expertise in large molecule bioanalytical testing to Reaction’s suite of premium drug discovery and development services.

Bioassay offers Good Manufacturing Practices (GMP) accredited potency assays and functional bioassays, Good Laboratory Practices (GLP) compliant services, and through PSL, peptide synthesis services, including peptide-specific antibody production and neoantigen synthesis. Personnel, equipment, and facilities from the acquired companies expanded Reaction’s presence in Germany, and have enabled its global customers to leverage Bioassay’s expansive portfolio of regulated clinical and commercial services.

Meeting global demand for large molecule services

Reaction Biology CEO John H. Johnson said of the acquisition: “Market demand is increasing globally for large molecule services as biopharmaceutical companies search for new treatment options for patients suffering with cancer and other serious diseases.”

“This transaction enabled Reaction Biology to add Bioassay GmbH’s impressive clinical phase and post-approval infrastructure, which includes large molecule capabilities, as well as its GMP and GLP accreditations, to our expanding suite of drug discovery and development services. As a result, we have been able to provide our customers with even broader offerings to meet their research and development goals,” said Mr. Johnson.

Expanded bioanalytical platform

Bioassay joint Managing Directors, Chief Operating Officer Dr. Sven Cords, and Chief Scientific Officer Dr. Axel Hohenstein, commented: “Reaction’s commitment to high quality science and reputation for providing customers a personalized and collaborative research experience were instrumental in our decision to join this outstanding company.”

“The infrastructure and resources gained from this acquisition have provided us with an even stronger platform from which to expand our bioanalytical capabilities and grow our customer base, all while continuing to deliver gold standard quality services,” Bioassay explained.

About Bioassay GmbH

Bioassay GmbH is a bioanalytical contract laboratory (CRO) specializing in the development, validation and routine performance of bioanalytical assays in the areas of Pharmacology and Toxicology.

Bioassay serves clients in the biotechnology, chemistry and cosmetics sectors and is particularly expert in carrying out potency assays under GMP for biopharmaceuticals, including therapeutic antibodies, hormones and cytokines. It offers a range of services based on in-vivo and in-vitro systems including potency assays (GMP) and toxicity Studies (GLP).

The Bioassay services portfolio focuses on the critical investigation areas of potency, efficacy, and safety, with panels that incorporate a wide range of specialized models and techniques.

Bioassay GmbH was privately founded in 2002 and since 2022 has formed part of the Reaction Biology Corporation. The company is located at Heidelberg’s Technology Park as part of a cluster of innovative biotech companies and institutions with links to Heidelberg University.

Learn more at:

About Reaction Biology

Founded in 2001, Reaction Biology is a global contract research organization (CRO) that provides drug discovery and development services to biopharmaceutical customers worldwide. Reaction specializes in supporting research goals with capabilities that include protein and peptide production, biochemical and biophysical assays, high throughput screening, exploratory toxicology, biomarker discovery tools, and an extensive array of cell-based and pharmacological assays modelling various diseases. Reaction also provides Good Manufacturing Practice (GMP) and Good Laboratory Practice (GLP) analytical and functional bioassays for testing potency, efficacy, and safety of large biological molecules, enabling clinical and commercial manufacturing batch release. Reaction has helped to advance many of its customers’ molecules through discovery and development pipeline stages into later clinical phases. These molecules may ultimately benefit patients living with cancer and other serious diseases. Reaction maintains one of the largest panels of kinase assays in the world with over 750 unique assays and performs more than 5,000 client projects annually with its over 2,000 validated assays.

Reaction has laboratory facilities in Malvern, PA, Hershey, PA, Freiburg, Germany, and now Heidelberg, Germany.

Learn more at


Click on Reaction Biology Acquires Bioassay GmbH to see original announcement.


Independent Contract Laboratory specializing in the development, validation and routine performance of bioanalytical assays in the Life Science area

Bioassay and Reaction Biology Corporation mark first anniversary of merger